Table 1 Demographic, clinical and pathologic characteristics of the 287 subjects comprising the study cohort
From: Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature
| Features | Bladder cancer (%) N = 213 | Controls (%) N = 74 |
|---|---|---|
| Age (years) | ||
| < 65 | 50 (23.5%) | 74 (100.0%) |
| > 65 | 150 (70.4%) | 0 (0.0%) |
| Unavailable | 13 (6.1%) | |
| Sex | ||
| Female | 48 (24.0%) | 16 (21.6%) |
| Male | 152 (76.0%) | |
| Unavailable | 13 (6.1%) | |
| Race | ||
| Caucasian | 162 (76.1%) %) | |
| Other | 30 (14.0%) | |
| Unavailable | 21 (9.9%) | |
| Tumor grade | ||
| High-grade | 175 (82.2%) | |
| Low-grade | 26 (12.2%) | |
| Unavailable | 12 (5.6%) | |
| Tumor stage | ||
| Ta | 49 (23.0%) | |
| Tis (CIS) | 20 (9.4%) | |
| T1 | 62 (29.1%) | |
| T2 | 31 (14.6%) | |
| >T3, N+ or M+ | 39 (18.3%) | |
| Unavailable | 12 (5.6%) | |
| Recurrence | ||
| Yes | 70 (32.9%) | |
| No | 143 (67.1%) |